TY - JOUR T1 - Common genetic variants identify targets for COVID-19 and individuals at high risk of severe disease JF - medRxiv DO - 10.1101/2020.12.14.20248176 SP - 2020.12.14.20248176 AU - J. E. Horowitz AU - J. A. Kosmicki AU - A. Damask AU - D. Sharma AU - G. H. L. Roberts AU - A. E. Justice AU - N. Banerjee AU - M. V. Coignet AU - A. Yadav AU - J. B. Leader AU - A. Marcketta AU - D. S. Park AU - R. Lanche AU - E. Maxwell AU - S. C. Knight AU - X. Bai AU - H. Guturu AU - D. Sun AU - A. Baltzell AU - F. S. P. Kury AU - J. D. Backman AU - A. R. Girshick AU - C. O’Dushlaine AU - S. R. McCurdy AU - R. Partha AU - A. J. Mansfield AU - D. A. Turissini AU - A. H. Li AU - M. Zhang AU - J. Mbatchou AU - K. Watanabe AU - L. Gurski AU - S. E. McCarthy AU - H. M. Kang AU - L. Dobbyn AU - E. Stahl AU - A. Verma AU - G. Sirugo AU - Regeneron Genetics Center AU - M. D. Ritchie AU - M. Jones AU - S. Balasubramanian AU - K. Siminovitch AU - W. J. Salerno AU - A. R. Shuldiner AU - D. J. Rader AU - T. Mirshahi AU - A. E. Locke AU - J. Marchini AU - J. D. Overton AU - D. J. Carey AU - L. Habegger AU - M. N. Cantor AU - K. A. Rand AU - E. L. Hong AU - J. G. Reid AU - C. A. Ball AU - A. Baras AU - G. R. Abecasis AU - M. A. Ferreira Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/02/19/2020.12.14.20248176.abstract N2 - The need to identify and effectively treat COVID-19 cases at highest risk for severe disease remains critical. We identified five common genetic loci (two novel) that modulate both COVID-19 susceptibility and severity, implicating TMPRSS2, IFNAR2, CCHCR1, TCF19 and SLC6A20 as potential targets. A high genetic burden was strongly associated with increased risk of hospitalization and severe disease among COVID-19 cases, especially among individuals with few known clinical risk factors.Competing Interest StatementJ.E.H., J.A.K., A.D., D.S., N.B, A.Y., A.M., R.L., E.M., X.B., D.S., F.S.P.K., J.D.B., C.OD., A.J.M., D.A.T., A.H.L., J.M., K.W., L.G., S.E.M, H.M.K., L.D., E.S., M.J., S.B., K.S.M, W.J.S., A.R.S., A.E.L., J.M., J.O., L.H., M.N.C., J.G.R., A.B., G.R.A., and M.A.F. are current employees and/or stockholders of Regeneron Genetics Center or Regeneron Pharmaceuticals. G.H.L.R., M.V.C., D.S.P., S.C.K. A.Bal., A.R.G., S.R.M., R.P., M.Z., K.A.R., E.L.H., C.A.B. are current employees at AncestryDNA and may hold equity in AncestryDNA. The other authors declare no competing interests.Funding StatementThe Penn Medicine BioBank is funded by a gift from the Smilow family, the National Center for Advancing Translational Sciences of the National Institutes of Health under CTSA Award Number UL1TR001878, and the Perelman School of Medicine at the University of Pennsylvania. All other authors have no sources of funding to acknowledge.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK Biobank obtained ethical approval for this study by the North West Multicenter Research Ethics Committee and all participants gave written informed consent to participate and be followed up. All additional participants from the Geisinger Health System MyCode Community Health Initiative, University of Pennsylvania Penn Medicine BioBank, and AncestryDNA customers provided informed consent to participate in research under IRB-approved protocols at each institution. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll genotype-phenotype association results reported in this study are available for browsing using the RGC COVID-19 Results Browser (https://rgc-covid19.regeneron.com). Data access and use is limited to research purposes in accordance with the Terms of Use (https://rgc-covid19.regeneron.com/terms-of-use). https://rgc-covid19.regeneron.com ER -